Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(88%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
3
38%
Ph phase_1
2
25%
Ph phase_2
2
25%

Phase Distribution

2

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Completed(1)

Detailed Status

Recruiting4
Active, not recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 33 (42.9%)

Trials by Status

recruiting450%
completed113%
active_not_recruiting338%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_3

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

NCT07683000
recruitingphase_3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961
recruitingphase_1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176
active_not_recruitingphase_3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
active_not_recruitingphase_2

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07683000Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Recruiting
NCT07682961Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Recruiting
NCT06819176Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Recruiting
NCT06333808Phase 3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Active Not Recruiting
NCT06532656Phase 2

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Active Not Recruiting
NCT07467018

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County

Recruiting
NCT05502341Phase 2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Active Not Recruiting
NCT03739866Phase 1

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8